Jim Cramer Says the Market Is “Dead Wrong” About These 5 Oversold Stocks
On Thursday, July 16, during the broadcast of Mad Money , Jim Cramer pushed back on the market's punishment of several blue-chip companies that just posted strong quarters.
JNJ - Johnson & Johnson
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$272.69
DETAILS
HIGH:
$305.00
LOW:
$220.00
MEDIAN:
$272.00
CONSENSUS:
$272.69
UPSIDE:
7.77%
Stock News
Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?
Four thousand dollars a month can cover a paid-off house, groceries, utilities, insurance, and modest travel in many parts of the country. It is also more than the $3,208 average monthly Social Security benefit SSA estimates for an aged couple, both receiving benefits, in January 2026. A portfolio producing another $4,000 a month can materially... Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?
J&J Stock Falls Despite Strong Q2 Beat & Higher 2026 View: Here's Why
JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.
I Was Wrong About Johnson & Johnson: Upgrading To Hold (Rating Upgrade)
Johnson & Johnson posted strong Q2 earnings. Sales of its NMDA receptor antagonist, called Spravato, for the treatment of depression, rose 41.1% year-on-year to $584 million in Q2. Also, J&J raised its 2026 adjusted diluted EPS guidance from $11.45-$11.65 to $11.6-$11.75.
The Portfolio That Pays All Your Car Repairs For Life
Few things ruin a Saturday morning faster than the words "your timing chain is going." Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those... The Portfolio That Pays All Your Car Repairs For Life
Johnson & Johnson Posts Upbeat Q2: IM Momentum Building Into 2027, Says Bullish Analyst
Johnson & Johnson (NYSE:JNJ) shares rose in early trading on Thursday, after the company reported upbeat second-quarter results.
Johnson & Johnson Raises 2026 Outlook After Q2 Earnings Beat
Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all. Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson.
DePuy Synthes Acquires Expanding Innovations™
RAYNHAM, Mass.--(BUSINESS WIRE)--DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes' Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment. Expanding Innovations (EI) is a commercial-stage medical technology company focused on developing and commercializing.
The Portfolio Blueprint for Building $20,000 a Month in Dividend Income
Twenty thousand dollars a month in dividends means $240,000 a year that has to arrive whether the market cooperates or not. Reaching it is a math problem before it is a stock-picking problem, and the math gets uncomfortable fast when you compare that target with current yields. The core equation is unforgiving: annual income divided... The Portfolio Blueprint for Building $20,000 a Month in Dividend Income
Ora Banda delivers record gold quarter as ‘DRIVE to 300’ expansion gathers momentum
Ora Banda Mining Ltd (ASX:OBM, OTC:ESGFF) has closed FY2026 with record quarterly gold production, strong cash flow and a larger resource base. The company...
Is Johnson & Johnson a Buy After Its Latest Earnings Report?
Many traded out of the pharmaceutical sector mainstay to leave it with a nearly 3% loss. While the company posted growth where it counts, the market seems to be expecting notable outperformance from large players in the industry these days.
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript
Johnson & Johnson (JNJ) Q2 2026 Earnings Call Transcript
Johnson & Johnson's Spravato sales growth supports psychedelic drug opportunity: Jefferies
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression treatment, with Jefferies writing that the drug's commercial performance supports the long-term market opportunity for the sector. Johnson & Johnson (NYSE:JNJ) reported worldwide second-quarter Spravato (esketamine nasal spray) sales of $584 million, up 25% from the first quarter, including US sales of $514 million.
Why Johnson & Johnson's Earnings Dip Looks Like a Buying Opportunity
Johnson & Johnson NYSE: JNJ is an elite income investment because of its Dividend King status, healthy balance sheet, and incredibly strong, defensive business model. Critical details include its product portfolio and pipeline, which are producing numerous catalysts simultaneously in 2026.
Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is up 24.03% year to date and 65.92% over the past year, riding oncology strength and a raised full-year outlook.
Wall Street Lunch: Dan Ives Teams Up With Yorkville Securities To Launch Merchant Bank
Tech analyst Dan Ives announced that he has teamed up with Yorkville Securities to form a new kind of merchant bank. Johnson & Johnson (JNJ) beat Q2 estimates and raised guidance, but EPS decline weighed on sentiment despite innovative medicine strength.
Stock Market Is Giving A Pristine Entry Point Into This 64-Year Dividend King
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories look nothing alike.
Nasdaq closes higher as Apple, soft PPI lift stocks
4:15pm: Apple surges, inflation cools Stocks finished higher on Wednesday as another softer-than-expected inflation report reinforced expectations that the...
Price Targets
Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter
$280.00
(was $249.75)
Ilya Zubkov
·
Johnson Rice
Johnson & Johnson price target raised to $305 from $265 at Scotiabank
$305.00
(was $248.94)
Scotiabank
Johnson & Johnson price target raised to $265 from $258 at Raymond James
$265.00
(was $250.50)
Raymond James
Johnson & Johnson (JNJ) PT Raised to $261 at Bernstein SocGenMember Login
$261.00
(was $250.49)
Johnson Rice
Johnson & Johnson price target raised to $282 from $275 at Goldman Sachs
$282.00
(was $247.02)
Goldman Sachs
Johnson & Johnson price target raised to $294 from $284 at Morgan Stanley
$294.00
(was $247.02)
Terence Flynn
·
Morgan Stanley
Johnson & Johnson price target raised to $272 from $263 at Wells Fargo
$272.00
(was $247.02)
Wells Fargo
Johnson & Johnson price target raised to $260 from $250 at Stifel
$260.00
(was $247.02)
Rick Wise
·
Stifel Nicolaus
Johnson & Johnson price target raised to $287 from $265 at RBC Capital
$287.00
(was $257.61)
RBC Capital
Johnson & Johnson price target raised to $284 from $283 at Morgan Stanley
$284.00
(was $267.24)
Terence Flynn
·
Morgan Stanley
Johnson & Johnson price target raised to $290 from $280 at HSBC
$290.00
(was $258.65)
HSBC
Johnson & Johnson price target raised to $270 from $266 at Guggenheim
$270.00
(was $253.56)
Vamil Divan
·
Guggenheim
Johnson & Johnson (JNJ) PT Raised to $270 at GuggenheimMember Login
$270.00
(was $253.29)
Johnson Rice
Johnson & Johnson upgraded to Outperform from Market Perform at Leerink
$265.00
(was $224.26)
David Risinger
·
Leerink Partners
Johnson & Johnson price target raised to $266 from $244 at Guggenheim
$266.00
(was $232.71)
Guggenheim
Johnson & Johnson price target raised to $283 from $267 at Morgan Stanley
$283.00
(was $239.66)
Morgan Stanley
Johnson & Johnson price target raised to $265 from $255 at RBC Capital
$265.00
(was $240.10)
RBC Capital
Johnson & Johnson price target raised to $250 from $220 at Stifel
$250.00
(was $240.10)
Rick Wise
·
Stifel Nicolaus
Johnson & Johnson price target raised to $255 from $234 at Barclays
$255.00
(was $240.10)
Matt Miksic
·
Barclays
Johnson & Johnson price target raised to $267 from $262 at Morgan Stanley
$267.00
(was $239.50)
Morgan Stanley